Controlled study designed to confirm previous compelling efficacy with preliminary data expected by the end of 2026 Pelareorep-based treatment regimen recently granted Fast Track Designation in 2L ...
Low dose alnodesertib plus gemcitabine met the primary endpoint of progression-free survival (PFS) versus gemcitabine alone ...
An international, randomized, double-blind, placebo-controlled Phase III study—the largest of its kind for mpox—found that ...
A 20-year follow-up of older adults in the ACTIVE randomized trial linked to Medicare claims found that speed of processing cognitive training with booster sessions was associated with a significantly ...
The results of a randomized controlled trial (RCT) indicate that meningococcal B vaccine is not effective at preventing ...
Effect on Travel Distance of a Statewide Regionalization Policy for Initial Breast Cancer Surgery The use of 90 mg/m 2 daunorubicin once daily in the context of classical 7 + 3 induction does not ...
"Disappointing" trial results, but some researchers remain hopeful ...
Global, randomized Phase 2 study to evaluate the addition of givastomig, a CLDN18.2 x 4-1BB bispecific antibody (8 mg/kg and ...
A phase 2 study of response-guided neoadjuvant sacituzumab govitecan and pembrolizumab (SG/P) in patients with early-stage triple-negative breast cancer: Results from the NeoSTAR trial. This is an ...
Idiopathic normal-pressure hydrocephalus is a neurologic disorder characterized by impaired gait, balance, cognition, and bladder control in older adults. The disorder is treated with shunt surgery, ...